On June 22, 2010
Amgen’s EPO Drugs Dodge a Bullet as Hematide Stumbles, but the Big Biotech’s Trials Aren’t Over
Amgen (AMGN)’s anemia franchise dodged a bullet yesterday when Affymax (AFFY) and Takeda reported mixed data from four Phase III trials of potential competitor Hematide — but Amgen isn’t totally out of the woods just yet.
…
0 Comments